Praxis Precision Medicines, Inc.
0.3M
$6.56B
-21.87
$-13.48
No price alerts set. Add an alert to get notified!
-21.87
7.55
$-13.48
-34.54%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals Inc.
|
$22.20 | -0.54% | 9.61 | $3.78B | 0.04 |
|
AKRO
Akero Therapeutics, Inc.
|
$54.65 | 0.00 | -15.31 | $4.50B | 0.00 |
|
CNTA
Centessa Pharmaceuticals plc
|
$39.69 | -0.43% | -27.27 | $5.34B | 0.01 |
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
$37.23 | 1.80% | -7.53 | $3.90B | 0.05 |
|
IMVT
Immunovant, Inc.
|
$24.50 | -2.39% | -9.58 | $4.99B | 0.00 |
|
KYMR
Kymera Therapeutics, Inc.
|
$85.40 | 0.55% | -23.14 | $6.97B | 0.05 |
|
LGND
Ligand Pharmaceuticals Incorporated
|
$199.59 | -0.02% | 31.64 | $3.98B | 0.44 |
|
SLNO
Soleno Therapeutics, Inc.
|
$39.49 | 6.76% | 100.52 | $2.12B | 0.01 |
|
VKTX
Viking Therapeutics, Inc.
|
$34.80 | 5.58% | -11.03 | $4.02B | 0.00 |
|
XENE
Xenon Pharmaceuticals Inc.
|
$56.85 | 0.28% | -13.03 | $4.49B | 0.01 |
* Peer stocks are selected based on market capitalization and sector
$356.00
$26.70
$0.00
0.00%
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
